International Psoriasis Council

International Psoriasis Council
subscribe
5   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Juul

van den Reek

,

MD, PhD

Scientific Researcher
Radboud University Medical Center
Nijmegen
,
Netherlands
2022 Fellow
Councilor Since: March 8, 2024
IPC Councilor
Request an Update
Dr. Juul van den Reek works as an MD/epidemiologist at the Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands, where she combines research with patient care in the specialized psoriasis clinic. Her research interest focuses on clinical epidemiology and, more specifically, evaluating real-world data of patients treated with biologics for inflammatory diseases. She coordinates the BioCAPTURE registry, a national psoriasis registry for biologics, and the BeNeBio consortium, a Dutch-Belgium study on dose reduction of biologics for psoriasis. She is the medical advisor for the Dutch Psoriasis Foundation journal and a Dutch Psoriasis guideline committee member. Dr. van den Reek studied with IPC Board Member Joel Gelfand during her IPC Fellowship at his Philadelphia, Pennsylvania, United States clinic. She has been an IPC Councilor since March 2024.
Last Updated:
03/01/2024

Areas of Interest

Evaluation of effectiveness, drug survival, and safety of biologics for psoriasis in practice (real-world evidence), planetary health and psoriasis (sustainable choices in psoriasis care, including dose reduction of biologics and remote care), epidemiology of psoriasis and its comorbidities, and the Influence of gender on outcomes of psoriasis treatment

IPC Committees / Groups

Editorial Committee, Regional Development Task Force

Languages Spoken

Dutch, English

Involvement with Other Organization(s)

Dr. van den Reek is the Dutch Psoriasis Patient Federation journal advisor. The patient federation is closely involved in Dr. van den Reek’s studies as a patient advisor in her research. In 2017, she was a fellow of the National Psoriasis Foundation (NPF).
Recent publications

Featured

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

PDF

The Global Burden of Pediatric Psoriasis: A Systematic Review.

View Report

PDF

IPC Psoriasis Disease Severity Reclassification: Update on Validity, Acceptance, and Implementation.

View Report

PDF

Investigation of the Applicability of Adult Definitions of Disease Severity for Psoriasis in a Pediatric Cohort: A…

Conflicts of interest Dr Al-Gawahiri carried out clinical trials for Janssen. All funding is not personal but goes to…

View Report

Video

The Epidemiology of Psoriasis.

In this Take Ten with IPC video, Dr. Juul van den Reek discusses the global epidemiology of psoriasis and highlights…

Watch Video

Blog

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD.

Learn about Juul van den Reek's experience as a 2022 participant in IPC's International Fellowship Program. In this…

Read More

PDF

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN).

Experts worldwide report on their experiences and deliver insight into the latest results and clinical studies. The…

View Report

Blog

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN)…

The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 –…

Read More

Blog

Focus on Psoriasis: A Report from the 2021 Hybrid Gene to Clinic Congress.

The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world…

Read More

PDF

Focus on Psoriasis – A Report from the 2021 Hybrid Gene to Clinic Congress.

View Report

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »
Monday, April 27, 2026

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026